Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant
(XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20 …

The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at
least rifampicin and isoniazid) represents a growing threat to public health and economic …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

The treatment of TB, both drug-susceptible and drug-resistant forms, should be based on
two principles: 1) the combination of drugs (at least four) to avoid selection pressure …

Over 480 000 cases of multidrug-resistant (MDR) tuberculosis (TB) occur every year
globally, 9% of them being affected by extensively drug-resistant (XDR) strains of …

After decades of neglect, tuberculosis (TB) drug research and development is attracting
renewed interest, with the discovery of several promising new drug candidates over the past …

Despite the low expensive and effective four-drug treatment regimen (isoniazid, rifampicin,
pyrazinamide and ethambutol) was introduced 40 years ago, TB continues to cause …

Multidrug-resistant tuberculosis has emerged worldwide, with an increasing incidence due
to failure of implementation of apparently effective first-line antituberculous therapy as well …

The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …